Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

Item

http://www.wikidata.org/entity/Q26738598

description

2016 nî lūn-bûn

@nan

2016 թուականին հրատարակուած գիտական յօդուած

@hyw

2016 թվականին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@ast

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@en

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@nl

type

Item

label

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@ast

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@en

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@nl

prefLabel

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@ast

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@en

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@nl

P1476

Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma

@en

P2093

Katherine A Janeway

http://www.w3.org/2001/XMLSchema#string

Michael W Bishop

http://www.w3.org/2001/XMLSchema#string

P2860

Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.

High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma

P304

1590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

244421

http://www.w3.org/2001/XMLSchema#string

P356

10.12688/F1000RESEARCH.8228.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27441088

http://www.w3.org/2001/XMLSchema#string

P932

4937817

http://www.w3.org/2001/XMLSchema#string